Glaukos Corp (GKOS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Glaukos Corp stock (GKOS) is currently trading at $109.60. Glaukos Corp PS ratio (Price-to-Sales) is 12.04. Analyst consensus price target for GKOS is $139.62. WallStSmart rates GKOS as Sell.
- GKOS PE ratio analysis and historical PE chart
- GKOS PS ratio (Price-to-Sales) history and trend
- GKOS intrinsic value — DCF, Graham Number, EPV models
- GKOS stock price prediction 2025 2026 2027 2028 2029 2030
- GKOS fair value vs current price
- GKOS insider transactions and insider buying
- Is GKOS undervalued or overvalued?
- Glaukos Corp financial analysis — revenue, earnings, cash flow
- GKOS Piotroski F-Score and Altman Z-Score
- GKOS analyst price target and Smart Rating
Glaukos Corp
📊 No data available
Try selecting a different time range
Smart Analysis
Glaukos Corp (GKOS) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, eps growth, institutional own.. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Glaukos Corp (GKOS) Key Strengths (4)
Revenue surging 35.70% year-over-year
Earnings per share surging 1896.00% year-over-year
100.55% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Glaukos Corp (GKOS) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 12.0x annual revenue
Very expensive at 8.9x book value
Growth is fairly priced, not cheap, not expensive
Supporting Valuation Data
Glaukos Corp (GKOS) Detailed Analysis Report
Overall Assessment
This company scores 44/100 in our Smart Analysis, earning a D grade. Out of 10 metrics analyzed, 4 register as strengths (avg 9.3/10) while 6 fall into concern territory (avg 1.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, EPS Growth, Institutional Own.. Growth metrics are encouraging with Revenue Growth at 35.70%, EPS Growth at 1896.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including PEG Ratio (1.64), Price/Sales (12.04), Price/Book (8.94) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -26.40%, Operating Margin at -18.90%, Profit Margin at -37.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -26.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 35.70% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
GKOS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
GKOS's Price-to-Sales ratio of 12.04x trades 30% below its historical average of 17.1x (27th percentile). The current valuation is 70% below its historical high of 40.11x set in Jul 2015, and 49% above its historical low of 8.09x in Mar 2020. Over the past 12 months, the PS ratio has compressed from ~15.3x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Glaukos Corp (GKOS) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Glaukos Corp is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 507M with 36% growth year-over-year. The company is currently unprofitable, posting a -37.0% profit margin.
Key Findings
Revenue growing at 36% YoY, reaching 507M. This pace significantly outperforms most MEDICAL DEVICES peers.
Generating 4M in free cash flow and 7M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -37.0% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can Glaukos Corp maintain 36%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Glaukos Corp.
Bottom Line
Glaukos Corp is a high-conviction growth story with revenue accelerating at 36% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -37.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Glaukos Corp(GKOS)
NYSE
HEALTHCARE
MEDICAL DEVICES
USA
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California.